GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 12th October, 2018

To,
The Manager,
Listing Department,
BSE Limited,
Bombay Stock Exchange,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Subject: Statement of Investor Complaints for the quarter ended 30th September, 2018.

Ref: Scrip code 956084 and ISIN INE988W07019

Dear Sir/Madam,

With reference to the subject matter, please find below the statement of investor complaints for Genlink Pharma Solutions Private Limited (formerly known as Genlink Pharma Investments Private Limited) as required under Regulation 13(3) of Chapter III of SEBI (Listing Obligations and Disclosure Requirements), 2015 for the quarter ended 30th September, 2018.

Particulars	Status of complaints
Investor complaints pending at the	Nil
beginning of the quarter	
Investor complaints received during the	Nil
quarter	
Investor complaints	Not applicable
disposed of during the quarter	
Investor complaints remaining unresolved at	Nil
the end of the quarter	

We kindly request you to take the above information on your records. Thanking you.

For Genlink Pharma Solutions Private Limited (Formerly Known As Genlink Pharma Investments Private Limited)

ANAND P SHAH

DN: c=IIV, G=PESODBI, U-34885*/B, 25-4.70=6925614292524816642ea178d8a9299750914f874ea27cb23d2fdcc1080672, postalCode=400088, sl=Kaharashtra, serialNumber=9b6362dd230a28722f9ce120900f57574439f5921b75f439476177db14bc820: cn=ANAND P5HAP

Anand Prafulchandra Shah Director & Compliance Officer DIN: 00597145

DII4. 005// 145